Jonathan S. Wolin - 24 Jun 2025 Form 4 Insider Report for Jaguar Health, Inc. (JAGX)

Role: Chief of Staff, Chief Compliance Officer and General Counsel
Signature: /s/ Jonathan S. Wolin
Issuer symbol: JAGX
Transactions as of: 24 Jun 2025
Net transactions value: +$23,100,000
Form type: 4
Filing time: 26 Jun 2025, 16:32:04 UTC
Previous filing: 02 Apr 2025
Next filing: 21 Jan 2026
SEC: View on sec.gov

Quoteable Key Fact

"Jonathan S. Wolin filed Form 4 for Jaguar Health, Inc. (JAGX) on 26 Jun 2025."

Quick Takeaways

This page summarizes Jonathan S. Wolin's Form 4 filing for Jaguar Health, Inc. (JAGX).
3 reported transactions and 3 derivative rows are listed below.
Filing timestamp: 26 Jun 2025, 16:32.

What Changed

Previous filing in this sequence was filed on 02 Apr 2025.
Current net transaction value: +$23,100,000.

Why This Matters

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Wolin Jonathan S.	Chief of Staff, Chief Compliance Officer and General Counsel	C/O JAGUAR HEALTH, INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO	/s/ Jonathan S. Wolin	26 Jun 2025	0001787587

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JAGX	Convertible Promissory Note	Disposed to Issuer	$450,000,000	-9,000	-100%	$50000.00	0	24 Jun 2025	Common Stock	9,000	$5.56	Direct	F1
transaction	JAGX	Convertible Promissory Note	Award	$473,100,000	+9,462		$50000.00	9,462	24 Jun 2025	Common Stock	9,462	$5.56	Direct	F1
transaction	JAGX	Warrant to Purchase Common Stock	Award		+18,262			9,000	24 Jun 2025	Common Stock	18,262	$2.70	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person disposed of a 6% convertible promissory note maturing on 6/30/2025 (the "Original Note") that was originally issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 in exchange for a new 6% convertible promissory note that matures on 1/30/2026 (the "New Note") in an issuer exchange offer. The New Note is convertible, at the reporting person's option, in part or in full, into an aggregate of 9,462 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share.
F2	As an inducement to enter into the issuer exchange offer, the reporting person received a warrant (the "Warrant") to purchase up to 18,262 shares of Common Stock with an exercise price of $2.70 per share. The Warrant is exercisable immediately upon receipt of stockholder approval and will expire on the earlier of (i) 18 months from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event.

Content

The reporting person disposed of a 6% convertible promissory note maturing on 6/30/2025 (the "Original Note") that was originally issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 in exchange for a new 6% convertible promissory note that matures on 1/30/2026 (the "New Note") in an issuer exchange offer. The New Note is convertible, at the reporting person's option, in part or in full, into an aggregate of 9,462 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share.

As an inducement to enter into the issuer exchange offer, the reporting person received a warrant (the "Warrant") to purchase up to 18,262 shares of Common Stock with an exercise price of $2.70 per share. The Warrant is exercisable immediately upon receipt of stockholder approval and will expire on the earlier of (i) 18 months from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event.

Remarks:

Chief of Staff, Chief Compliance Officer and General Counsel